Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.
Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.
Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical firm, will host an in-person investor day on June 26, 2024, at the Lotte Palace New York Hotel. The event will begin at 8:30 a.m. EDT. Key opinion leaders, including Aleš Linhart of Charles University and Naomi Schlesinger of the University of Utah, will discuss the treatment landscapes for Fabry disease and uncontrolled gout, respectively. Special focus will be on clinical results for Elfabrio® (pegunigalsidase alfa) and PRX-115. Protalix's CEO, Dror Bashan, will also present a corporate overview. A live Q&A session will follow the presentations.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins via its ProCellEx® plant cell-based system, announced its participation at the 2024 BIO International Convention in San Diego, California. The convention, hosted by the Biotechnology Innovation Organization (BIO), is the largest industry event, gathering global biotech and biopharmaceutical executives. Dror Bashan, President and CEO of Protalix, will present on June 3, 2024, at 2:30 PM PDT in Theater 1, providing updates on corporate developments to industry leaders and investors.
Protalix BioTherapeutics, Inc. (PLX) reported financial results for Q1 2024, highlighting encouraging top-line results from the phase I clinical trial of its uricase candidate, PRX-115. The company plans to expand the trial into a phase II study. Despite a decrease in revenues, Protalix remains focused on research and development efforts to build its product pipeline. The company's cash position is strong, enabling it to repay convertible notes due in September 2024 and sustain ongoing operations.
Protalix BioTherapeutics, Inc. will announce its financial results for the first quarter of 2024 on May 10, 2024, along with a business and clinical update. The company focuses on developing and commercializing recombinant therapeutic proteins. Investors can join the conference call and webcast to discuss the results and recent developments. The call details are provided for easy access.
FAQ
What is the current stock price of Protalix Biother (PLX)?
What is the market cap of Protalix Biother (PLX)?
